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Abstract 
Introduction. Diabetes mellitus, a dysglycaemic disorder is causing a huge financial budget 
to society, government agencies and individuals every year. Diabetic patients are at the risk 
of long-term macro– and microvascular damages. Current therapies for diabetes include 
lifestyle modification and pharmacological interventions. However, conventional oral anti–
hyperglycemic drugs produce a range of side effects such as hypoglycemia; therefore safer 
and more effective medications are required to manage diabetes and prevent the long-term 
complications. Fucoidan represents a large class of highly sulfated and water-soluble 
polysaccharides presents in all of the brown algae. Its antidiabetic effect has been reported in 
the literature. The objective of this study was to investigate the inhibitory effects of three 
different types of fucoidan on the activity of intestinal enzyme, ɑ-glucosidase, which is 
involved in the facilitation of glucose absorption. 
Methods. α–glucosidase enzyme was extracted from the rat–intestinal acetone powder. The 
enzyme activity of α–glucosidase was determined using an enzyme substrate 4-Nitrophenyl 
β-D-glucuronide (PNPG) and enzyme extract. The enzyme kinetics of α–glucosidase was 
performed using different concentrations of substrate. The calculation of Vmax and Km were 
carried out based on Lineweaver–Burk plot. The inhibitory effect of three different types of 
fucoidan (Undaria pinnatifida, Fucus vesiculosus, Fucus synergy) was investigated. The 
stock solution containing 1000 μg ml-1 of fucoidan was prepared. Different concentrations of 
fucoidan solutions were prepared by serially diluting the stock solution. Acarbose and Milli–
Q water were used as positive control and negative control respectively. In enzyme assay, a 
reaction mixture contained enzyme extract, substrate and fucoidan.  
Results and discussion. The activity of extracted α–glucosidase was found to be 0.0381 U 
ml-1. The Vmax and Km values were 0.2885 µg min
-1 and 8.8339 μg ml-1 respectively. In the 
  
inhibitory assay, the maximum percentage of inhibition of acarbose was 61.11%. In contrast, 
the maximum inhibitory effects of fucoidan extracted from Fucus synergy was 7.57%, 
followed by the extracts of Fucus vesiculosus (6.14%) and Undaria pinnatifida (3.30%). 
Conclusion. Three different types of fucoidan investigated in the current study had negligible 
inhibitory effect on the activity of on α–glucosidase enzyme. 
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1.1 Marine algae and discovery history in Australia 
Marine algae, also known as seaweed is a wide group of organisms which require oxygen and 
light to produce nutrition for growth (1). Multiple taxonomical methods such as kingdom-
division-class axis are developed to classify these organisms because it is impossible to place 
all of the existing algae into specific categories (2). However, the most common used 
category is based on their colour, namely phaeophytes (brown algae), rhodophytes (red 
algae), chlorophytes (green algae) (3) and cyanophytes (blue-green algae) (4). The extracts 
obtained from marine algae have various therapeutic functions, for instance, anti–tumor, 
antiviral and anti–coagulant activities (5).  
 
The earliest description about Australian marine algae was made by a scientist from New 
South Wales as Conferva umbilicata in 1800 BC, which is currently known as Microdictyon 
umbilicatum. After that, Captain Vancouver collected marine algae systematically in his 
expedition in 1791. Thirty–nine years later, Charles Fraser became the first Australian who 
collected marine algae along the Swan River in Western Australia. Evidence has revealed that 
the Southern Australian region, including Tasmania is rich in marine algae resources, 
probably due to favorable growth conditions (6). 
 
1.2 The worldwide consumption, cultivation and utilisation of marine algae 
According to statistics reported in 2009, seaweeds contribute to approximately 25% of daily 
utilisation, including food consumption, agricultural field and health care industry (7) . The 
annual consumption is dominated by a large portion of brown algae (66.5%), followed by 
figures of red algae (33%) and green algae (5%) (8). Interestingly, nearly 90% dry seaweed 
products just come from six countries, namely Chile, Korea, Japan, China, United Kingdom 
and France (9). Nevertheless, the consumption of seaweed products differs significantly from 
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Asia to Western countries. By comparison,  seaweeds are not authorised as food in European 
countries until 1990 (10). With the epidemic requirement of seaweed products, artificial 
cultivation becomes the most productive way because of the high profits and ease of growth 
(11).  
 
1.3 Nutritional content and potential effects of marine algae 
Thirty years ago, the principal use of seaweeds was dominated by various industrial 
applications, for example, being used as gelling and thickening agents. Polysaccharide 
extracts such as alginate, carrageenan and agar did not used as food supplement until the year 
of 1990 in Europe. France was the first country to legislate them for human consumption 
(10). So far marine algae have been proved to be rich in various nutritional components such 
as vitamins, proteins, dietary fibres and minerals, and also have shown great interests in 
nutritional area. Undoubtedly, they are one of the promising food sources to cope with the 
shortage of food supplementation. 
 
1.3.1 Protein and nitrogen  
Generally, high protein and nitrogen content of marine algae is more important in food and 
agricultural industries (1). For example, some species show an increasing value for flavour 
formula  because of high content of aspartate and glutamate (4). However, a species 
difference is observed for this aspect. Typically, brown seaweed contains relatively smaller 
proteinic percentage (average 5~15% of the dry weight), in comparison with that of red and 
green seaweed which are as high as 10~30%. Overall, marine algae are rich in proteins while 
poorer in digestibility (12). Although there are no substantial evidences indicating the 
digestibility of algal proteins, proteolytic enzymes such as pepsin and pancreatin are assumed 
to be responsible for the degradation of algal proteins (6,15,16).  
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1.3.2 Fatty acid 
Lipid profiles of marine algae suggest that seaweeds have potential health benefit and turn 
out to be an option for hyperlipoidemic patients’ diets (13). Seaweeds contain many essential 
fatty acids which are good for a balance diet, while low in lipid composition (between 1.5% 
and 4% of dry matter) (14). Marine algae have a remarkable level of polyunsaturated fatty 
acids (PUFAs) such as omega 3 (n-3) and omega 6 (n-6) fatty acids (FAs) and function well 
in preventing or modulating coronary heart disease. Some essential dietary fatty acids, for 
example, linoleic acids, are also detected in the seaweeds (15). 
 
1.3.3 Polysaccharide and dietary fibres 
Polysaccharides exist in many kinds of marine algae and express heterogeneous structures 
(16, 17). Algae polysaccharides can be divided into three major classes according to their 
functions and locations. The most common class is storage polysaccharides such as laminarin 
in brown seaweeds and starch in green seaweeds (16). Another common class is called 
cellular mucilage polysaccharides and other minor polysaccharides are found on the cell wall, 
for instance, carrageenans extracted from red seaweeds (14). Cell-wall polysaccharides have 
been proved to have various medicinal properties due to their sulfated groups (5, 20, 21). 
Most algae polysaccharides are proposed to be dietary fibre because there is a lack of 
digestive enzymes in human intestine; thus they cannot be considered as a reliable energy 
source (14). However, dietary fibre extracted from seaweeds contributes to the nutritional 
meal replacement for over-weight patients. Fucoidan, known as sulfated fucans, is an 
important member of sulfated polysaccharides and exhibit many important biological 
properties.   
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1.3.4 Minerals and vitamins 
The mineral content of marine algae varies with growth environment, seasons, species and 
manufacturing methods. Generally, the composition of minerals is as high as 40%, containing 
various essential minerals, such as potassium, calcium, sodium, magnesium, phosphate, and a 
remarkable percentage of iodine (1, 12, 18).  Therefore, edible marine algae have potential to 
be a prospective source of mineral supplementation product. 
 
In addition to protein, dietary fibres and minerals, seaweeds are also considered to be a good 
source of vitamins. For example, red and green seaweeds contain significant levels of vitamin 
A and B (19), while part of the brown seaweeds are potential sources of vitamin C (12). 
 
1.4 Fucoidan 
1.4.1 General structure and physicochemical properties 
Brown seaweeds produce multiple branched polysaccharides with species–specific sugar 
substituents. Algal fucoidans represent a family of highly sulfated and water-soluble 
polysaccharides presenting in all of the brown algae. They compose up to 25–30% of the 
seaweed dry weight. The biosynthesis pattern and the species diversity contribute to the 
heterogeneous structures of fucoidan (17, 20). Recent findings suggest that the backbone of 
fucoidan is constituted to α–(13) linked fucose with substantial sulfate ester and L-fucose 
groups on C–2 or C–4 position (21). However, fucoidan structure is difficult to be analysed 
precisely due to the variability of linkage types and species deviation generally. 
 
1.4.2 Structure–biological activities relationship 
The algal fucans have some repeating pattern but are heterogeneous with the time of 
collection and species difference. It has been reported that their biological activities are 
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highly related with their structures. The position and amount of sulfated groups are two 
significant parameters that determine the biological activities of fucoidan (1, 22). It has also 
reported that molecule weight and size of fucoidan contribute to qualitative difference in 
previous biological studies (5, 25). For example, low molecule weight fucoidan (LMWF) 
(15-20 kDa) has a pro-angiogenic effect and better anti–coagulant outcomes than those in 
large size. Therefore, enzymatic degradation methods are used in the manufacturing process, 
aimed to produce a LMWF while retaining the maximum amount of sulfated groups (5).  
 
1.4.3 Different biological activities of the brown seaweed fucoidans 
One consequence of the heterogeneous structures of fucoidan is that each unique structure 
has a potential to be recognised by a specific receptor (5). Even though mechanisms by which 
fucoidan insert their biological actions remain controversial due to the complex structures, 
studies have indicated that fucoidan has considerably valuable therapeutic effects such as 
anti–coagulant (23, 24), anti–tumor (25), anti-inflammatory (16), antiviral (26, 27) and 
antioxidation (17). 
 
1.4.3.1 Anti–coagulant and anti–thrombotic activity 
Fucoidan has structural similarity in sulfated content with heparin, thus it exhibits anti–
coagulant activity. A study that used activated partial thromboplastin time (APTT) mode has 
shown that fucoidan exhibits strong inhibitory effect on thrombin activity of platelet (28). 
Some studies illustrate that therapeutic outcomes and mode of action vary with the structure 
of fucoidan. For instance, increase in the sulfate content can improve the anti–coagulant 
activity by between 10 and 19% (21). Moreover, straight sulfated fucoidan show indirect 
inhibitory effect on thrombin while highly branched types can inhibit the activity of thrombin 
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without other factors (28).  Because of the anti–coagulant activity of fucoidan, it can be 
considered as a promising alternative to heparin.  
 
1.4.3.2 Anti–virals 
In recent years, both in vitro and in vivo studies have demonstrated the antiviral activities of 
sulfated polysaccharides such as fucoidan. Fucoidan has an interesting function of anti RNA 
and DNA viruses (1). It has been reported that fucoidan could have protective antiviral 
activity via direct inhibition of viral replication and activating the host immune defense 
system (21).  
 
1.4.3.3 Anti–tumor and anti–oxidant activities 
Fucoidan is suggested to be a promising agent for anticancer and anti–tumor therapies. Both 
native and oversulfated fucoidans have been investigated. The results have shown that 
increasing the extent of sulfation can enhance the inhibition of tumor cell growth through 
stronger suppression on angiogenesis (29). Besides of its anti–tumor activity, fucoidans 
extracted from edible seaweeds are effective anti–oxidants.  
 
1.4.3.4 Anti-inflammatory activity 
The anti-inflammatory activity of fucoidan has also been investigated. Some extracts of 
fucoidan can decrease the neutrophil extravasation and transmigration at a dose of 15 mg/kg 
in an acute peritonitis rat model (28). The inhibitory effect of fucoidan on leukocyte 
recruitment in the inflammatory model may be associated with the release of nitric oxide (NO) 
(21).  
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1.4.4 Toxicity of fucoidan 
Development and application of fucoidan as therapeutic agent has been an important research 
topic. However, data on its safety profile obtained from in vitro and in vivo studies of 
fucoidan are relatively limited. Two available research articles (30, 31) have reported the 
toxicities associated with fucoidan administration. Fucoidan extracted from Undaria 
pinnatifida did not cause genotoxicity when the oral dose was lower than 1000 mg/kg body 
weight per day in the tested animals. Whereas for fucoidan extracted from Laminaria 
japonica did not show signs of toxicity unless the dose was higher than 900 mg/kg body 
weight per day in the tested animals. The administration of fucoidan is considered to be safe 
when given at therapeutic doses. Nevertheless, the long-term side effects and toxicities 
associated with fucoidan require further investigation. 
 
1.5 Diabetes 
The incidents of diabetes mellitus, a dysglycaemic disorder is increasing world widely, 
causing a huge financial burden to society and individuals every year. According to the latest 
annual report of Intentional Diabetes Federation, at the end of 2011, there are more than 366 
million or 8.3 % of global adult population been diagnosed with diabetes, and the figure is 
predicted to be double at the end of 2030 (32). Diabetes is a metabolic disease characterized 
by high blood glucose level with the fasting glucose level more than 140 mg/dl (33). Diabetic 
patients are at the risk of long-term macro- and microvascular damages that can lead to 
further severe complications such as blindness, coronary artery disease and renal failure (34, 
35). 
 
Diabetes is classified into four main categories, namely type 1 or insulin-dependent diabetes, 
type 2 or non-insulin-dependent diabetes, gastrointestinal diabetes and other specific types 
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such as impaired glucose tolerance (IGT) (33, 35). Current antihyperglycaemic treatments 
only focus on controlling exacerbation and such available approaches have a range of adverse 
effects such as hypoglycemia, weight gain and nausea(36). Therefore, it is of importance to 
develop new antidiabetic therapies that could provide more efficient therapeutic outcomes 
with fewer side effects. In particular, decreasing the postprandial glucose levels through 
retarding the conversion of carbohydrates, fat and proteins into glucose is considered to be a 
promising approach because this method has a lower risk of hypoglycemia and weight gain 
which are frequently seen with the administration of other anti-diabetic agents. Nowadays, 
the inhibitory effects of natural products on digestive starch enzymes, for example, ɑ-
glucosidase, have drawn much attention in this aspect (37). 
 
1.5.1 Carbohydrate metabolism and postprandial hyperglycaemia  
Plasma glucose level is tightly controlled within a narrow range in nondiabetic people. After 
taking meals, increase in the postprandial glucose stimulates the secretion of insulin from 
pancreas β–cells (38).  The balance between the rate of carbohydrate absorption from the 
gastrointestinal tract and the rate of utilisation is determined by several parameters such as 
nutrient type, digestive enzymes and reaction time of peripheral tissues to insulin secretion 
(39). In diabetic patients, postprandial hyperglycaemia could be observed as a consequence of 
insulin resistance or insulin deficiency (40). Evidences have suggested that postprandial 
hyperglycaemia itself is a significant risk factor of cardiovascular diseases (CVDs) and 
contributes to mortality rate (34). Studies have demonstrated that the risk of myocardial 
infarction is two to three fold greater in patients who have developed postprandial 
hyperglycaemia, compared with those with normal glucose tolerance (39). CVDs are 
associated with a soaring level of mortality in the patients with impaired dependent diabetes 
(IGT) and type 2 diabetes (34, 41). 
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1.5.2 Currently available treatments of diabetes 
The main purpose of diabetic therapies is to control the blood glucose level and to prevent the 
complications such as CVDs (24, 29, 31). Lifestyle modification which involves dietary 
changes and exercise becomes a key strategy of prophylaxis.  However, this approach alone 
is not sufficient for long-term glycaemic management. Therefore, pharmacological 
intervention is required to maintain the treatment outcomes (34). There are three main types 
of oral antidiabetics, namely insulin secretagogues, insulin sensitisers and inhibitors of 
carbohydrate absorption (38).  
 
Recently, inhibitory effect of both synthesised and natural therapies on starch digesting 
enzymes such as α–glucosidase have been investigated since inhibiting the rate of 
carbohydrate absorption provides a safe way, with a lower risk of hypoglycaemia and greater 
benefits on preventing diabetic complicates than conventional medications (36).  
 
1.5.2.1 Synthetic α–glucosidase inhibitors: acarbose and miglitol 
The development of ɑ–glucosidase inhibitors such as acarbose and miglitol has provided a 
new approach in managing diabetes. Basically, these molecules reversibly bind to the 
carbohydrate region of α–glucosidase (an intestinal enzyme) This would reduce the digestion 
of carbohydrates and hence decrease the intestinal absorption of glucose (24, 28, 32). The 
major side effects of α–glucosidase inhibitors is gastrointestinal disturbance such as diarrhoea 
and  abdominal discomfort, which are diminished with reduced dose (39). Acarbose and 
miglitol are two common drugs that can inhibit the activity of α–glucosidase enzyme. 
Diarrhoea, flatulence and abdominal distension are the major reported side effects of 
acarbose and miglitol. Large randomized clinical studies such as Non-Insulin Dependent 
Diabetes Mellitus (STOP-NIDDM) randomised trial (42, 43) and randomized double-blind 
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trial (44) have reported that both acarbose and miglitol showed superior outcomes in 
preventing postprandial hyperglycaemia and CVDs on patients with IGT or established type 2 
diabetes, compared with insulin secretagogues and insulin sensitisers. Unlike the use of 
sulphonylureas and glinides, both of which are widely used for management of type 2 
diabetes, administrating acarbose or miglitol alone is not associated with weight gain and 
hypoglycaemia (34, 45). Additionally, acarbose and miglitol are safer to use with metformin 
and other oral antihyperglycaemic agents due to less drug-drug interactions (33, 35).  
 
1.5.2.2 Natural α–glucosidase inhibitors from plants and marine algae 
Other alternative sources for α–glucosidase inhibitors are plants and marine algae. The active 
extracts from plants and seaweeds provide more flexible food consumption choice for 
diabetic patients. Studies have shown that some plants extracts have hypoglycemic effects 
(37, 46, 47). For example, phenolic constituents of the heartwood of Pterocarpus marsupium 
can decrease the blood glucose level significantly in diabetic rat, in comparison of metformin 
(46). The anti–diabetic effect of both oversulfated fucoidan (OSF) and native focidan (NF) 
are also assessed via enzymatic reaction kinetics and their inhibitory activity against starch 
digestive enzymes (47). The results illustrated that the NF had little inhibitory effect on α–
amylase while OSF can reduce the starch digestibility by 12%. Since fucoidan has a large 
molecular weight and low digestibility, it is less likely to be absorbed from the 
gastrointestinal tract. Hence, one possible mechanism of action for its potential anti–diabetic 
effects could be inhibition of intestinal enzymes.  
 
 
 
 
12 
 
1.6 Objectives 
The aim of this study was to investigate the inhibitory effects of fucoidans from Undaria 
pinnatifida, Fucus vesiculosus and Fucus synergy on the activity of ɑ-glucosidase. 
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Abstract 
Context. Diabetes causes a significant burden to the society and individuals. Current 
treatments exhibit many limitations. Therefore more effective and safer medications are 
required for its treatment. 
Objective. The aim of this study was to investigate the inhibitory effects of fucoidans from 
Undaria pinnatifida, Fucus vesiculosus and Fucus synergy on the activity of ɑ-glucosidase. 
Materials and methods. Enzyme activity and enzyme kinetics of α–glucosidase enzyme 
extracted from rat–intestinal acetone powder were carried out using standard calibration 
curve of p–nitrophenol. Then enzyme inhibition assay was carried out using fucoidan from 
three different sources. Water and acarbose were used as negative and positive controls 
respectively. 
Results. The enzyme activity, Km and Vmax of α–glucosidase were 0.0381 U ml-1, 8.8339 μg 
and 0.2885 µg ml-1 respectively. Acarbose showed inhibition of α–glucosidase activity while 
three different types of tested fucoidan showed very little or no activity. 
Discussion and conclusion. Experimental results showed negligible inhibitory effect of 
fucoidan on the activity of α–glucosidase.  
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Introduction 
Diabetes is a group of heterogeneously metabolic disorders, characterised by hyperglycemia 
and glucose intolerance. It is mainly divided into insulin-dependent diabetes mellitus (IDDM) 
and non-insulin-dependent diabetes mellitus (NIDDM). Destruction of pancreatic beta-cells 
contributes to type I diabetes (IDDM), whereas insulin resistance or relative insulin 
deficiency is believed to be one major cause of type 2 diabetes (NIDDM) (1). Long–term 
abnormal glucose metabolism in diabetes provokes damage to blood vessels and double the 
risk of cardiovascular diseases (CVDs). The diabetic complications could be both 
macrovascular and microvascular, such as ischemic heart disease and blindness (2). 
Generally, the elderly patients with long–term poor blood glucose control are more likely to 
develop nephropathy, retinopathy, neuropathy and CVDs. By the end of 2000, 3% of the 
Western population had non–insulin–dependent diabetic mellitus (NIDDM) and 40% of these 
were patients over 60 years old. (3). Among these complications, CVDs such as coronary 
heart disease, stroke and peripheral vascular disease are the main reasons of mortality in 
diabetic patients. Many studies have indicated that postprandial hyperglycemia together with 
other risk factors, for example, smoking contribute to the development of CVDs (4). 
Therefore, preventing the onset of CVDs and correcting the postprandial hyperglycemic state 
are two core strategies in diabetic treatment. Current approaches include lifestyle 
modification and medication intervention (5). However, current pharmacological therapy is 
still facing a great challenge because evidence shows that some conventional oral anti-
hyperglycemic agents increase the cardiovascular mortality (6). In the recent years, natural 
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products (7, 8) and chemically synthesised agents targeted on digestive starch enzymes, for 
example, ɑ-glucosidase, have proven to be effective in treating postprandial hyperglycemia. 
Acarbose, a synthesised ɑ-glucosidase inhibitor exhibited promising antidiabetic effect. It not 
only reduces postprandial hyperglycemia but also reduces the risk of CVDs by 49% (9). 
However, a study in 1994 revealed that approximately 46% of subjects complained about 
gastrointestinal discomfort such as flatulence and diarrhoea and about 2% did not tolerate 
acarbose (5). To reduce the side effects associated with synthesised α–glucosidase inhibitors, 
natural products extracted from marine algae such as fucoidan have been investigated for 
their potentially inhibitory effect on ɑ-glucosidase.  
Marine algae represents a large family of organisms and contains high content of sulfated 
polysaccharides which exhibit a variety of biological activities such as anti–oxidant (10), 
anti–viral and anti–bacterial (11), anti–tumor, anti–inflammatory and anti–coagulant (12). 
Fucoidan is a water soluble sulfated polysaccharide (13). A small in vitro study has indicated 
that fucoidan can potentially inhibit the activity of α–glucosidase enzyme (14) probably 
because of structural similarity to acarbose. 
Many factors, such as the structure of fucoidan and types of seaweed sources can influence its 
inhibitory effect on α–glucosidase activity. Some studies also indicate that those factors make 
it hard to determine the anti–diabetic effect of fucoidan (15, 16). Hence, more research on 
anti-hyperglycemic activity of fucoidan is still needed. The objective of this study was to 
investigate the inhibitory effects of fucoidans from Undaria pinnatifida, Fucus vesiculosus 
and Fucus synergy on the activity of ɑ-glucosidase. 
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Methods 
Materials 
Rat–intestinal acetone powder, sodium carbonate, 4–nitrophenol, acarbose, monobasic 
potassium phosphate, dibasic potassium phosphate and 4–nitrophenyl α–D–glucopyranoside 
(PNPG) were purchased from Sigma–Aldrich (New South Wales, Australia). Three different 
types of fucoidan (Undaria pinnatifida, Fucus vesiculosus, Fucus synergy) were generously 
donated by Marinova Pty Ltd (Tasmania, Australia). 
Extraction of mammalian α–glucosidase  
The method described by Mohamed and co–workers was modified for the extraction of α–
glucosidase from rat–intestinal acetone powder (17). Briefly, rat–intestinal acetone powder 
(200 mg) was mixed with ice cold phosphate buffer (4 ml, 50 mM, pH 6.8). The suspension 
was then sonicated for 45 minutes using ultrasonic bath (Sonorex RK–100, Bendelin 
Electronic, Berlin, Germany) kept at approximately 0 to 4C. The resultant mixture was 
centrifuged (Eppendof centrifuge, model number 5417R, Hamburg, Germany) at 4C and 
13,000 rpm for 30 minutes. The supernatant was then carefully removed and stored at – 20C 
for further experiments. 
Determination of enzyme activity 
The activity of α–glucosidase was determined using PNPG (an enzyme substrate). The 
reaction between the enzyme and its substrate was initiated by mixing 10 µl of enzyme 
extract and 20 µl of 1 mM PNPG with 50 µl of 50 mM phosphate buffer pH 6.8. The 
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enzyme–substrate mixture was then incubated in a Bioer mixing block (MB–102, Hangzhou, 
China) at 37 C (500 rpm) for 30 minutes. The reaction was stopped using 50 µl of 0.1 M 
sodium carbonate. The intensity of colour, which was proportional to the activity of enzyme, 
was read at 405 nm using a micro–plate reader (Thermo Scientific Multiskan60, 
Massachusetts, United States of America). A solution of 4-nitrophenol (100 µg ml-1) was 
diluted with a 50 mM of phosphate buffer to obtain 5 different concentrations (5, 10, 15, 20 
and 25 µg ml-1). A standard calibration curve (n=3) was generated by analysing these 
standards at 405 nm using a microtiter plate reader. Control samples (n=3) were prepared and 
analysed in a similar way except the enzyme was denatured by placing it in boiling water for 
10 minute. The activity of enzyme (U ml-1) was calculated using a following formula:  
                            
where m (product) is the mass of p–nitrophenol, MW (product) is the molecular weight of p–
nitrophenol. 
Enzyme kinetics of α–glucosidase 
 Kinetic study of the enzymatic reaction was carried out using different concentrations of 
PNPG in the presence of enzyme. A solution (n=3) containing 50µl of 50 mM phosphate 
buffer (pH 6.8), 10 µl of enzyme and 20 µl of different concentrations (ranging from 0.5 to 
16 µg ml-1) of PNPG was incubated at 37 C using a mixing block for 30 minutes. The 
reaction was then stopped by adding 50 µl of 0.1 M sodium carbonate, followed by 
incubation in mixing block for approximately 1 minute. The intensity of colour was measured 
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at 405 nm using a microtiter plate reader. Control samples (n=3) were prepared and analysed 
in a similar way except the enzyme was denatured by placing it in boiling water for 10 
minutes. Samples were prepared in triplicate and analysed in duplicate. Lineweaver–Burk 
plot was used to determine maximum reaction rate (Vmax) and Michaelis constant (Km) of the 
enzyme (17, 18). 
Inhibitory assay 
The inhibitory effect of fucoidan on α–glucosidase was investigated using varying 
concentrations (ranging from 0.01 to 1000 µg/ml) of three different types of fucoidan 
(Undaria Pinnatifida, Fucus Vesculosus, Fucus Synergy). Enzyme (0.04U ml-1, 50 µl) was 
mixed with 20 µl of each concentration of inhibitor in eppendorf tube and incubated for 10 
minutes at 37 C and 500 rpm. Technically, various concentrations of inhibitor were diluted 
from a stock solution (7 mg ml-1) which provided 1000 µg/ml of fucoidan or acarbose in the 
final reaction mixture (140 µl). The fucoidan powder (70 mg) was placed in a 10 ml 
volumetric flask and then was sonicated using ultrasonic bath until all particles dissolved. 
After this, the stock solution was diluted to obtain different concentrations (0.05, 0.1, 1, 2.5, 
7.5, 10, 50, 100, 500, 1000 µg ml-1) of fucoidan. The preparation of positive control 
(acarbose) followed a similar pattern, whereas Milli–Q water was used instead of tested 
sample in the negative controls. Enzyme (0.04U/ml) and its activity were obtained based on 
the process of extraction of mammalian α–glucosidase enzyme and determination of enzyme 
activity respectively. A solution (n=3) containing enzyme extract and different concentrations 
of fucoidan was incubated at 37C for 10 minutes. PNPG (1 mM, 20 µl) was added to the 
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enzyme–fucoidan mixture to initiate the enzyme–substrate reaction. The mixture was then 
incubated for 30 minutes at 37C in a mixing block. Sodium bicarbonate (50 µl of 0.1M) was 
added to stop the enzyme–substrate reaction. At end of assay, the intensity of the colour was 
measured at 405 nm using a microtiter plate reader. The inhibitory effect of fucoidan and 
positive control were calculated using a following formula:             
                  010
MC
MSMC
inhibition % 

    
where MC and MS are mass of product converted in the negative control and that of sample 
or the positive control respectively. 
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Results  
Enzyme activity of α–glucosidase 
Enzyme activities of four different extracts were found to be 0.0076, 0.0098, 0.0237 and 
0.0381 U ml-1. The fourth enzyme extract (0.0381 U ml-1) was used for the enzyme inhibitory 
assay. 
Enzyme inhibitory assay of α–glucosidase 
Three different extracts of fucoidan assessed in enzyme inhibitory assay had negligible effect 
when compared with acarbose. The maximum percentage of inhibition of acarbose was 
61.11%, achieved at a concentration of 1000 μg ml-1, and showed a consistent tendency 
during the enzyme inhibitory assay. In contrast, the maximum percentage of inhibition of 
fucoidan extracted from Fucus Synergy was 7.57%, followed by the extracts of Fucus 
vesiculosus (6.14%) and Undaria pinnatifida (3.30%) (Figure 1). As fucoidan did not show 
increase in inhibition with increase in concentration of it, it can be confirmed that all the 
tested fucoidan extracts did not show inhibitory effect on the enzyme. 
Vmax and Km of α–glucosidase 
The enzyme kinetics study showed that the enzyme had Km and Vmax values of 8.8339   μg 
ml-1 and 0.2885 μg min-1 respectively (Figure 2). 
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Discussion 
Although the inhibitory effect of fucoidan from two commercial seaweeds (Fucus vesiculosus 
and Ascophyllum nodosum) on yeast α–glucosidase has been reported in 2012 (19), this study 
re-assessed its anti-hyperglycemic effect on the same enzyme for three main reasons. First of 
all, yeast α–glucosidase instead of mammalian source was used in previous study (19). The 
second reason to revisit is they have used four concentrations of fucoidan ranging from 0.005 
to 0.05 μg ml-1 in 5 ml of final enzyme–substrate–inhibitor solution where as higher 
concentration of fucoidan is included in my experiment. Moreover they used negative control 
only but both negative and positive controls were used in our study. Third reason is that the 
activity of fucoidan was not investigated in duplicate or triplicate. Multiple analysis of the 
same sample is important for the reliability of the results (20). 
Another study in 2012 showed that fucoidan extract from Fucus vesiculosus showed the 
maximum percentage inhibition of 51.4% (19), whereas fucoidan from same source and other 
two sources did not exhibit inhibition on the same enzyme in our study. This could be due to 
property of fucoidan shows highly species–specific characteristics and some other parameters 
such as harvesting period and growth conditions also contribute to variance on its inhibitory 
effect (13).   
The extraction of enzyme was influenced by sonication time. Increase in sonication time 
increased the amount of enzyme that can be extracted from the rat intestinal powder, thus 
higher enzyme activity was obtained with longer sonication time. For example, the enzyme 
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activities of α–glucosidase was 0.0076 U ml-1 after 30 minutes of sonication time, compared 
to 0.0381 U ml-1 after 60 minutes of sonication. 
Michaelis constant (Km) in enzyme kinetics indicated the affinity of α–glucosidase to PNPG. 
Km also equals to the concentration of substrate at which the reaction takes place at one half 
of its maximum reaction rate and this value is reversely proportional to the affinity (21). In 
this study, Km value indicated the required concentration of PNPG and the reaction time to 
achieve equilibrium. Relevant studies on mammalian α–glucosidase are quite limited. 
However, one study in 1983 showed Km and Vmax values of yeast α–glucosidase from 
Lactobacillus acidophilus on PNPG as 7.9988 μg ml-1 and 0.001807 μg min-1 respectively 
after 30 minutes reaction (22). My experimental result showed that Km value was similar to 
yeast α–glucosidase but Vmax was 160 times higher than it. That means yeast α–glucosidase 
and mammalian α–glucosidase have similar affinity to PNPG, whereas the rate of 
transformation from substrate to product by using rat α–glucosidase is 160 times more than 
that of yeast α–glucosidase.  Additionally, according to the Km value, the concentration of 
PNPG at which the reaction takes place at half of Vmax is 0.0635 μM; therefore, only 
approximate 0.127 μM of PNPG is required to achieve the Vmax, compared with 1 mM of 
PNPG employed in this study. 
However, due to time constrain it was not possible to investigate the activity of fucoidan 
extracted from other sources. Also, this study did not investigate the influence of various 
parameters such as seasonal variation and extraction procedures on the inhibitory effect of 
fucoidan. 
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Conclusions 
The inhibitory effects of three types of fucoidan were negligible, compare with acarbose, 
which reached a maximum percentage inhibition of 61% at 30 minutes reaction time using 
1000 μg ml-1 acarbose. The Vmax and Km values of rat α–glucosidase were 0.2885 μg min-1 
and 8.8339 μg ml-1 respectively. Enzyme activity of α–glucosidase was 0.0381 U ml-1. 
According to the discussion above, α–glucosidase has high affinity to PNPG. The 
concentration of PNPG (1 mM) and the reaction time (30 minutes) were sufficient to achieve 
the Vmax. 
 
 
 
 
 
 
 
 
 
 
31 
 
Declaration of interest 
The author has declared no potential conflicts of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
List of figures 
Figure 1  
The inhibitory effect of fucoidan extracted from Fucus synergy, Undaria pinnatifida and 
Fucus vesculosus on the activity of ɑ–glucosidase, in comparison with acarbose at the same 
concentrations 
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Figure 2 
Partial determination of enzyme kinetics of ɑ–glucosidase using different concentrations of 
PNPG (ranging from 0.5 to 16 µg ml-1). The reciprocal values of intercept of X axis and Y 
axis indicate Vmax and Km respectively. 
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